While Neogenomics Inc. has overperformed by 0.39%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NEO rose by 1.70%, with highs and lows ranging from $21.22 to $11.03, whereas the simple moving average jumped by 1.53% in the last 200 days.
On May 01, 2024, Craig Hallum started tracking Neogenomics Inc. (NASDAQ: NEO) recommending Buy. A report published by BTIG Research on December 29, 2023, Reiterated its previous ‘Buy’ rating for NEO. Stephens also Upgraded NEO shares as ‘Overweight’, setting a target price of $18 on the company’s shares in a report dated August 21, 2023. BTIG Research May 09, 2023d its ‘Neutral’ rating to ‘Buy’ for NEO, as published in its report on May 09, 2023. The Benchmark Company’s report from February 24, 2023 suggests a price prediction of $20 for NEO shares, giving the stock a ‘Buy’ rating. Needham also rated the stock as ‘Buy’.
Analysis of Neogenomics Inc. (NEO)
Further, the quarter-over-quarter increase in sales is 13.86%, showing a positive trend in the upcoming months.
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Neogenomics Inc.’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of -8.88% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 7.22, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and NEO is recording an average volume of 955.68K. On a monthly basis, the volatility of the stock is set at 4.77%, whereas on a weekly basis, it is put at 4.44%, with a gain of 11.85% over the past seven days. Furthermore, long-term investors anticipate a median target price of $20.45, showing growth from the present price of $15.57, which can serve as yet another indication of whether NEO is worth investing in or should be passed over.
How Do You Analyze Neogenomics Inc. Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 1.15%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 99.48% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
NEO shares are owned by institutional investors to the tune of 99.48% at present.
